Pharmaceuticals
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a l...
2024-01-24 17:49
1448
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...
2024-01-24 11:37
1159
Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
* Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events * Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduction of -6.8% from baseline, compared to -0.9% for...
2024-01-24 10:00
1299
INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the devel...
2024-01-24 08:22
1267
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction. "We are all delighted to see CBL-514 showing its ...
2024-01-23 21:12
1394
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...
2024-01-23 21:00
2848
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...
2024-01-23 18:35
1056
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis - Primary efficacy endpoints: * NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD A...
2024-01-23 12:17
1375
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...
2024-01-23 11:53
1249
Extensive R&D Capabilities：ICP DAS - BMP to Showcase a Broad Range of Medical-Grade TPU at MD&M West 2024, U.S.
HSINCHU, Jan. 23, 2024 /PRNewswire/ -- ICP DAS – BMP, Asia's first medical-grade thermoplastic polyurethane (TPU) supplier, will make its MD&M West debut inthe United States. Kicking off 2024, the company presents a comprehensive range of top-quality medical-grade TPU series to the foremost expe...
2024-01-23 10:06
2024
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
GAITHERSBURG, Md., Jan. 23, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and ...
2024-01-23 06:00
2462
NK CellTech Announces FDA Clearance for Clinical Trial of NK010
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- On January 17, 2024, NK CellTech Co., Ltd. (NK CellTech), a leading biotech company focused on the development of NK cellular therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of NK010, the non-genetically modified ...
2024-01-22 20:10
1318
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
MELBOURNE, Australia, Jan. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be he...
2024-01-22 19:00
1340
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Company expects to record a total reven...
2024-01-22 07:50
3140
Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today
SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- On January 13, 2024 local time, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of its "Sanyou Super Trillion Peptide Molecule Discovery Platform". The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral ...
2024-01-20 08:00
2304
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
BEIJING and SAN FRANCISCO, Jan. 19, 2024 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Socie...
2024-01-20 06:30
2371
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestin...
2024-01-19 21:50
1584
Call for Application for 2024 Tsinghua Amgen Scholars Program
BEIJING, Jan. 19, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thr...
2024-01-19 15:32
2557
Harbour BioMed Announces Positive Profit Alert
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-01-19 12:52
5028
Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific
* Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year inAsia Pacific * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development...
2024-01-18 12:00
1512
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 324 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 304 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 276 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
10237
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
8606
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
8129
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
7646
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7167
